Vertex Pharmaceuticals reported landmark Phase 3 results for povetacicept, a dual BAFF/APRIL inhibitor targeting IgA nephropathy, a progressive kidney disease affecting millions worldwide. In the Week 36 interim analysis of the RAINIER trial, patients achieved a 52% reduction in proteinuria from baseline — a 49.8% improvement over placebo (P<0.0001). Vertex shares climbed more than 5% on the news.

Secondary endpoints were equally striking: the drug reduced serum Gd-IgA1 levels by 77.4% and achieved hematuria resolution in 85.1% of treated patients, both with high statistical significance versus placebo.

The company plans to complete its full BLA submission to the FDA by the end of March, using a priority review voucher to cut the review timeline from ten to six months. If approved, povetacicept would become a first-in-class treatment for IgA nephropathy, a disease with limited options that can progress to kidney failure.